MiNK Therapeutics Inc Sustainability Reports
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900Z7778N8ZY89B90
FIGI: BBG012J84WM7
4 reports from 2021 to 2024
